

## Heterogeneity of lipid and protein cartilage profiles associated with human osteoarthritis with or without type 2 diabetes mellitus

<sup>a</sup>Maastricht MultiModal Molecular Imaging (M4i) institute, Division of Imaging Mass Spectrometry, Maastricht, NL

<sup>b</sup>Maastricht University Medical Center, Department of Orthopedic Surgery, Maastricht, NL

<sup>c</sup>Maastricht University Medical Center, Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht, NL

<sup>d</sup>Maastricht University Medical Center, Department of Internal Medicine, Division of Rheumatology, and Care and Public Health Research Institute (CAPHRI), Maastricht, NL

### Supporting information




Table S1. Patient information.

Table S2. Significantly up and down-regulated proteins found in OA/T2DM<sup>-</sup> compared to OA/T2DM<sup>+</sup>.

Table S3. Top 10 enriched pathways associated to the significant up and down-regulated proteins found in OA/T2DM<sup>-</sup> compared to OA/T2DM<sup>+</sup>.

Table S4. Assignments of 15 lipid species based on targeted MS/MS experiments performed at high-mass resolution.

Figure S1. Sample collection and processing.

Figure S2. Example of the spatial distribution of SM and LPC species in OA/T2DM<sup>-</sup> and OA/T2DM<sup>+</sup> patients.

Figure S3. Linear discriminant analysis of superficial and deep layers of both groups independently.

**Table S1. Patient information.** The (\*) displayed the samples used for the comparative MALDI-MSI experiments. (BMI: Body mass index; KL: Kellgren-Lawrence).

|  | Sample number | Age | Gender | Affected knee | BMI           | KL score      |
|--|---------------|-----|--------|---------------|---------------|---------------|
| <b>OA/T2DM<sup>-</sup><br/>patients<br/>(n=10)</b> | 1*            | 78  | Male   | Left          | 25.0          | 2             |
|  | 2*            | 61  | Male   | Left          | 32.0          | 3             |
|  | 3*            | 80  | Female | Left          | 30.5          | 4             |
|  | 4*            | 82  | Male   | Left          | 24.3          | 4             |
|  | 5*            | 59  | Female | Right         | 25.7          | 3             |
|  | 6*            | 71  | Male   | Left          | 26.9          | 3             |
|  | 7             | 67  | Female | Left          | 24.0          | 3             |
|  | 8             | 77  | Female | Left          | Not specified | Not specified |
|  | 9             | 75  | Male   | Left          | 28.0          | 4             |
|  | 10            | 66  | Female | Right         | 27.0          | 4             |
| <b>OA/T2DM<sup>+</sup><br/>patients<br/>(n=10)</b> | 1*            | 86  | Male   | Left          | 24.9          | 4             |
|  | 2*            | 70  | Female | Right         | 34.9          | 3             |
|  | 3*            | 72  | Male   | Right         | 32.4          | 4             |
|  | 4*            | 78  | Male   | Left          | 35.6          | 4             |
|  | 5*            | 81  | Male   | Right         | 24.9          | 3             |
|  | 6*            | 75  | Male   | Left          | 27.7          | 3             |
|  | 7             | 75  | Female | Left          | 33.3          | 2             |
|  | 8             | 56  | Female | Left          | 37.2          | Not specified |
|  | 9             | 73  | Male   | Right         | 28.4          | 4             |
|  | 10            | 58  | Male   | Right         | 23.9          | 4             |

**Table S2. Significantly up and down-regulated proteins found in OA/T2DM<sup>-</sup> compared to OA/T2DM<sup>+</sup>.** The FC cut-off is at 1.5-fold and adjusted p-value is  $\leq 0.05$ . 75 proteins were more abundant in OA/T2DM<sup>-</sup> samples whereas 40 were more abundant in OA/T2DM<sup>+</sup>. References of relevant proteins in the context of OA or T2DM have been included.

| Protein Name  | Fold change | p-value  |
|---|-------------|----------|
| Carbonyl reductase [NADPH] 3  | 0.01        | 1.99E-16 |
| Plastin-2   | 0.01        | 1.99E-16 |
| C-X-C motif chemokine 10  | 0.01        | 1.99E-16 |
| Cell surface glycoprotein MUC18                                     | 0.01        | 1.99E-16 |
| Aminopeptidase N  | 0.01        | 1.99E-16 |
| Band 3 anion transport protein                                      | 0.01        | 1.99E-16 |
| Glutathione hydrolase 5 proenzyme <sup>62</sup>                     | 0.01        | 1.99E-16 |
| Calponin-2  | 0.01        | 1.99E-16 |
| Olfactomedin-like protein 1 <sup>61</sup>                           | 0.01        | 1.99E-16 |
| Neural cell adhesion molecule 1                                     | 0.01        | 1.99E-16 |
| Catenin beta-1  | 0.01        | 1.99E-16 |
| Serum amyloid A-4 protein   | 0.01        | 1.99E-16 |
| Tartrate-resistant acid phosphatase type 5                          | 0.01        | 1.99E-16 |
| Properdin <sup>61</sup>   | 0.01        | 1.99E-16 |
| Lysyl oxidase homolog 1   | 0.01        | 1.99E-16 |
| Cadherin-13   | 0.01        | 1.99E-16 |
| Protein-glutamine gamma-glutamyltransferase E                       | 0.01        | 1.99E-16 |
| U6 snRNA-associated Sm-like protein LSM2                            | 0.01        | 1.99E-16 |
| Endoplasmic reticulum aminopeptidase 1                              | 0.01        | 1.99E-16 |
| Peptidyl-prolyl cis-trans isomerase FKBP5 <sup>62</sup>             | 0.01        | 1.99E-16 |
| Cytochrome b-c1 complex subunit Rieske, mitochondrial <sup>62</sup> | 0.01        | 1.99E-16 |
| NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial       | 0.01        | 1.99E-16 |
| Osteopontin <sup>61</sup>   | 0.08        | 1.99E-16 |
| Peroxiredoxin-like 2A   | 0.11        | 1.99E-16 |
| Keratocan   | 0.24        | 2.71E-05 |
| Microsomal glutathione S-transferase 1                              | 0.24        | 3.72E-08 |
| Carbonic anhydrase 1 <sup>61, 62</sup>                              | 0.24        | 7.42E-13 |
| Casein kinase II subunit alpha                                      | 0.28        | 4.49E-06 |
| Prostacyclin synthase   | 0.29        | 1.13E-03 |
| Dipeptidyl peptidase 4 <sup>62</sup>                                | 0.30        | 2.93E-03 |
| Collagen alpha-1(I) chain <sup>61, 62</sup>                         | 0.30        | 4.33E-09 |
| Fibronectin type III domain-containing protein 1 <sup>62</sup>      | 0.31        | 1.79E-03 |
| Apolipoprotein A-I <sup>42, 43, 44, 61</sup>                        | 0.31        | 1.35E-08 |
| Ras-related protein Rap-1A <sup>62</sup>                            | 0.31        | 1.41E-06 |
| Ubiquitin-conjugating enzyme E2 K                                   | 0.32        | 6.00E-04 |

|   |      |          |
|---|------|----------|
| MAM domain-containing protein 2 <sup>61</sup>                       | 0.32 | 2.17E-03 |
| Short-chain specific acyl-CoA dehydrogenase, mitochondrial          | 0.32 | 4.33E-03 |
| Apolipoprotein A-II   | 0.34 | 4.50E-03 |
| Histidine triad nucleotide-binding protein 2, mitochondrial         | 0.35 | 2.21E-02 |
| Collagen alpha-2(IV) chain <sup>62</sup>                            | 0.35 | 6.38E-03 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12       | 0.36 | 3.06E-02 |
| ATP synthase subunit e, mitochondrial <sup>62</sup>                 | 0.36 | 9.09E-03 |
| Sushi repeat-containing protein SRPX <sup>61, 62</sup>              | 0.37 | 8.86E-03 |
| Fatty acid synthase <sup>62</sup>                                   | 0.40 | 4.01E-02 |
| Liver carboxylesterase 1  | 0.41 | 4.77E-02 |
| Secreted phosphoprotein 24 <sup>61, 62</sup>                        | 0.42 | 1.74E-02 |
| Pigment epithelium-derived factor <sup>61</sup>                     | 0.43 | 2.53E-04 |
| Insulin-like growth factor-binding protein 6 <sup>62</sup>          | 0.44 | 4.16E-02 |
| Leucine-rich alpha-2-glycoprotein                                   | 0.44 | 8.81E-03 |
| 5'-nucleotidase   | 0.44 | 5.68E-04 |
| Small ubiquitin-related modifier 3                                  | 0.44 | 2.46E-03 |
| SPARC <sup>61</sup>   | 0.45 | 1.13E-04 |
| Superoxide dismutase [Mn], mitochondrial <sup>61</sup>              | 0.47 | 2.32E-03 |
| BTB/POZ domain-containing protein KCTD12                            | 0.47 | 3.10E-02 |
| Collagen alpha-2(I) chain <sup>61, 62</sup>                         | 0.48 | 3.19E-03 |
| Dermatopontin <sup>61, 62</sup>                                     | 0.49 | 5.12E-03 |
| Tetranectin <sup>61</sup>   | 0.49 | 5.41E-03 |
| Vitrin <sup>61, 62</sup>  | 0.49 | 5.51E-03 |
| Protein-glutamine gamma-glutamyltransferase 2                       | 0.49 | 5.72E-03 |
| 60S ribosomal protein L23a <sup>61</sup>                            | 0.49 | 3.39E-02 |
| 60S ribosomal protein L7a <sup>61, 62</sup>                         | 0.50 | 7.94E-03 |
| ATP synthase subunit gamma, mitochondrial                           | 0.50 | 1.53E-02 |
| Collagen triple helix repeat-containing protein 1 <sup>61, 62</sup> | 0.50 | 9.20E-03 |
| Extracellular superoxide dismutase [Cu-Zn] <sup>61, 62</sup>        | 0.51 | 1.08E-02 |
| Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-12  | 0.51 | 1.73E-02 |
| Histone H2A type 2-B  | 0.51 | 3.67E-02 |
| Keratinocyte proline-rich protein                                   | 0.52 | 5.82E-03 |
| 60S ribosomal protein L13a  | 0.53 | 3.33E-02 |
| Cytochrome b reductase 1 <sup>62</sup>                              | 0.54 | 3.47E-02 |
| Rho GDP-dissociation inhibitor 2                                    | 0.54 | 3.99E-02 |
| Collagen alpha-1(XII) chain <sup>61, 62</sup>                       | 0.54 | 3.39E-02 |
| Asporin <sup>61</sup>   | 0.54 | 3.75E-02 |
| Histone H2B type 1-K <sup>61</sup>                                  | 0.54 | 4.01E-02 |
| Hemopexin <sup>61, 62</sup>   | 0.55 | 2.46E-02 |
| CCN family member 2   | 0.57 | 4.41E-02 |
| Cartilage intermediate layer protein 1                              | 1.51 | 8.64E-03 |
| Serine protease HTRA3   | 1.52 | 6.97E-03 |
| Ribonuclease 4  | 1.55 | 4.77E-03 |
| Angiogenin  | 1.57 | 4.09E-03 |

|   |        |          |
|---|--------|----------|
| Apolipoprotein A-IV <sup>63</sup>                                       | 1.59   | 2.83E-03 |
| Platelet-derived growth factor C  | 1.63   | 2.50E-03 |
| Serine protease HTRA1 <sup>64</sup>                                     | 1.63   | 1.64E-03 |
| Lysozyme C  | 1.71   | 5.68E-04 |
| Metalloproteinase inhibitor 3   | 1.73   | 4.28E-04 |
| Nucleobindin-1  | 1.78   | 2.17E-02 |
| Alpha-crystallin A chain  | 1.79   | 1.80E-04 |
| Matrilin-3  | 1.81   | 1.34E-04 |
| Enolase-phosphatase E1  | 1.83   | 8.52E-03 |
| Phospholipase A2, membrane associated <sup>46, 47, 48, 49, 61, 81</sup> | 1.90   | 3.30E-05 |
| Metalloreductase STEAP4   | 1.94   | 5.97E-06 |
| 40S ribosomal protein S21   | 1.94   | 2.20E-05 |
| Retinal dehydrogenase 1   | 2.42   | 9.10E-07 |
| Transthyretin   | 2.95   | 4.90E-12 |
| Calcium-activated chloride channel regulator 1                          | 3.00   | 6.17E-09 |
| Protein ABHD13  | 3.85   | 1.99E-16 |
| Gamma-crystallin B  | 4.96   | 1.99E-16 |
| Gamma-crystallin C  | 5.05   | 1.99E-16 |
| Gamma-crystallin A  | 5.43   | 1.99E-16 |
| Beta-crystallin A3  | 6.35   | 1.99E-16 |
| Regenerating islet-derived protein 3-alpha                              | 10.72  | 1.99E-16 |
| Desmin  | 100.00 | 1.99E-16 |
| Glutathione S-transferase Mu 4  | 100.00 | 1.99E-16 |
| Defensin-6  | 100.00 | 1.99E-16 |
| Fatty acid-binding protein, liver                                       | 100.00 | 1.99E-16 |
| High mobility group protein HMG-I/HMG-Y                                 | 100.00 | 1.99E-16 |
| Beta-crystallin A2  | 100.00 | 1.99E-16 |
| Glycine amidinotransferase, mitochondrial                               | 100.00 | 1.99E-16 |
| Transmembrane glycoprotein NMB  | 100.00 | 1.99E-16 |
| E3 ubiquitin/ISG15 ligase TRIM25  | 100.00 | 1.99E-16 |
| Dihydropyrimidinase   | 100.00 | 1.99E-16 |
| Neutrophil elastase   | 100.00 | 1.99E-16 |
| Beta-crystallin B1  | 100.00 | 1.99E-16 |
| C-C motif chemokine 24  | 100.00 | 1.99E-16 |
| Nepriylisin   | 100.00 | 1.99E-16 |
| Leucine-rich repeat-containing protein 15                               | 100.00 | 1.99E-16 |

**Table S3. Top 10 enriched pathways associated to the significant up and down-regulated proteins found in OA/T2DM<sup>-</sup> compared to OA/T2DM<sup>+</sup>. (A) Top 10 enriched pathways in the OA/T2DM<sup>-</sup> group from WikiPathways database. (B) Top 10 enriched pathways in the OA/T2DM<sup>-</sup> group from KEGG database. (C) Top 10 enriched pathways in the OA/T2DM<sup>+</sup> group from WikiPathways database. (D) Top 10 enriched pathways in the OA/T2DM<sup>+</sup> group from KEGG database. The (\*) displays the pathways related to lipid regulation.**

| A WikiPathways database (Human) - OA/T2DM <sup>-</sup> group     |            |   | OA/T2DM <sup>+</sup> vs OA/T2DM <sup>-</sup> |          |
|--|------------|---|--|----------|
| Pathway description  | Protein ID | Protein name  | Fold change                                  | P-value  |
| WP3601 - composition of lipid particles*                         | P02647     | Apolipoprotein A-I  | 0.31   | 1.35E-08 |
|  | P02652     | Apolipoprotein A-II   | 0.34   | 4.50E-03 |
|  | P35542     | Serum amyloid A-4 protein                                     | 0.01   | 1.99E-16 |
| WP1533 - vitamin B12 metabolism*                                 | P02647     | Apolipoprotein A-I  | 0.31   | 1.35E-08 |
|  | P04179     | Superoxide dismutase [Mn], mitochondrial                      | 0.47   | 2.32E-03 |
|  | P08294     | Extracellular superoxide dismutase [Cu-Zn]                    | 0.51   | 1.08E-02 |
| WP4522 - metabolic pathway of LDL, HDL and TG*                   | P02647     | Apolipoprotein A-I  | 0.31   | 1.35E-08 |
|  | P02652     | Apolipoprotein A-II   | 0.34   | 4.50E-03 |
| WP12 - osteoclast signaling                                      | P10451     | Osteopontin   | 0.08   | 1.99E-16 |
|  | P13686     | Tartrate-resistant acid phosphatase type 5                    | 0.01   | 1.99E-16 |
|  | P10620     | Microsomal glutathione S-transferase 1                        | 0.24   | 3.72E-08 |
| WP408 - oxidative stress   | P04179     | Superoxide dismutase [Mn], mitochondrial                      | 0.47   | 2.32E-03 |
|  | P08294     | Extracellular superoxide dismutase [Cu-Zn]                    | 0.51   | 1.08E-02 |
|  | P02452     | Collagen alpha-1(I) chain                                     | 0.30   | 4.33E-09 |
| WP3967 - miR-509-3p alteration of YAP1/ECM axis                  | P09486     | SPARC   | 0.45   | 1.13E-04 |
|  | P35542     | Serum amyloid A-4 protein                                     | 0.01   | 1.99E-16 |
| WP176 - folate metabolism*                                       | P02647     | Apolipoprotein A-I  | 0.31   | 1.35E-08 |
|  | P04179     | Superoxide dismutase [Mn], mitochondrial                      | 0.47   | 2.32E-03 |
|  | P08294     | Extracellular superoxide dismutase [Cu-Zn]                    | 0.51   | 1.08E-02 |
|  | P08123     | Collagen alpha-2(I) chain                                     | 0.48   | 3.19E-03 |
| WP2911 - miRNA targets in ECM and membrane receptors             | P08572     | Collagen alpha-2(IV) chain                                    | 0.35   | 6.38E-03 |
|  | P36269     | Glutathione hydrolase 5 proenzyme                             | 0.01   | 1.99E-16 |
| WP100 - glutathione metabolism                                   | P15144     | Aminopeptidase N  | 0.01   | 1.99E-16 |
|  | Q9UI09     | NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 | 0.36   | 3.06E-02 |
| WP111 - electron transport chain (OXPHOS system in mitochondria) | P47985     | Cytochrome b-c1 complex subunit Rieske, mitochondrial         | 0.01   | 1.99E-16 |
|  | P36542     | ATP synthase subunit gamma, mitochondrial                     | 0.50   | 1.53E-02 |
|  | P49821     | NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial | 0.01   | 1.99E-16 |
|  | P56385     | ATP synthase subunit e, mitochondrial                         | 0.36   | 9.09E-03 |
|  |            |   |  |          |

**B** KEGG database (Human) - OA/T2DM<sup>+</sup> group

| Pathway description                | Protein ID | Protein name  | OA/T2DM <sup>+</sup> vs OA/T2DM <sup>-</sup> |          |
|------------------------------------|------------|---|--|----------|
|                                    |            |   | Fold change                                  | P-value  |
| protein digestion and absorption   | P02452     | Collagen alpha-1(I) chain                                     | 0.30   | 4.33E-09 |
|                                    | P27487     | Dipeptidyl peptidase 4  | 0.30   | 2.93E-03 |
|                                    | P08123     | Collagen alpha-2(I) chain                                     | 0.48   | 3.19E-03 |
|                                    | P08572     | Collagen alpha-2(IV) chain                                    | 0.35   | 6.38E-03 |
|                                    | Q99715     | Collagen alpha-1(XII) chain                                   | 0.54   | 3.39E-02 |
| riboflavin metabolism*             | P13686     | Tartrate-resistant acid phosphatase type 5                    | 0.01   | 1.99E-16 |
| ECM-receptor interaction           | P02452     | Collagen alpha-1(I) chain                                     | 0.30   | 4.33E-09 |
|                                    | P08123     | Collagen alpha-2(I) chain                                     | 0.48   | 3.19E-03 |
|                                    | P08572     | Collagen alpha-2(IV) chain                                    | 0.35   | 6.38E-03 |
|                                    | P10451     | Osteopontin   | 0.08   | 1.99E-16 |
| glutathione metabolism             | P36269     | Glutathione hydrolase 5 proenzyme                             | 0.01   | 1.99E-16 |
|                                    | P15144     | Aminopeptidase N  | 0.01   | 1.99E-16 |
|                                    | P10620     | Microsomal glutathione S-transferase 1                        | 0.24   | 3.72E-08 |
| oxidative phosphorylation          | Q9UI09     | NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 | 0.36   | 3.06E-02 |
|                                    | P47985     | Cytochrome b-c1 complex subunit Rieske, mitochondrial         | 0.01   | 1.99E-16 |
|                                    | P36542     | ATP synthase subunit gamma, mitochondrial                     | 0.50   | 1.53E-02 |
|                                    | P49821     | NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial | 0.01   | 1.99E-16 |
|                                    | P56385     | ATP synthase subunit e, mitochondrial                         | 0.36   | 9.09E-03 |
|                                    | P36269     | Glutathione hydrolase 5 proenzyme                             | 0.01   | 1.99E-16 |
| arachidonic acid metabolism*       | Q16647     | Prostacyclin synthase   | 0.29   | 1.13E-03 |
|                                    | O75828     | Carbonyl reductase [NADPH] 3                                  | 0.01   | 1.99E-16 |
|                                    | P36269     | Glutathione hydrolase 5 proenzyme                             | 0.01   | 1.99E-16 |
| taurine and hypotaurine metabolism | P36269     | Glutathione hydrolase 5 proenzyme                             | 0.01   | 1.99E-16 |
| huntington disease                 | Q9UI09     | NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 | 0.36   | 3.06E-02 |
|                                    | P47985     | Cytochrome b-c1 complex subunit Rieske, mitochondrial         | 0.01   | 1.99E-16 |
|                                    | P04179     | Superoxide dismutase [Mn], mitochondrial                      | 0.47   | 2.32E-03 |
|                                    | P36542     | ATP synthase subunit gamma, mitochondrial                     | 0.50   | 1.53E-02 |
|                                    | P49821     | NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial | 0.01   | 1.99E-16 |
|                                    | P21980     | Protein-glutamine gamma-glutamyltransferase 2                 | 0.49   | 5.72E-03 |
| focal adhesion                     | P02452     | Collagen alpha-1(I) chain                                     | 0.30   | 4.33E-09 |
|                                    | P08123     | Collagen alpha-2(I) chain                                     | 0.48   | 3.19E-03 |
|                                    | P62834     | Ras-related protein Rap-1A                                    | 0.31   | 1.41E-06 |
|                                    | P08572     | Collagen alpha-2(IV) chain                                    | 0.35   | 6.38E-03 |
|                                    | P10451     | Osteopontin   | 0.08   | 1.99E-16 |
|                                    | P35222     | Catenin beta-1  | 0.01   | 1.99E-16 |
| fatty acid biosynthesis*           | P49327     | Fatty acid synthase   | 0.40   | 4.01E-02 |

**C** WikiPathways database (Human) - OA/T2DM<sup>+</sup> group

| Pathway description                                   | Protein ID | Protein name                              | OA/T2DM <sup>+</sup> vs OA/T2DM <sup>-</sup> |          |
|---|------------|---|--|----------|
|   |            |   | Fold change                                  | P-value  |
| WP1589 - folate-alcohol and cancer pathway hypotheses | P00352     | Retinal dehydrogenase 1                   | 2.42   | 9.10E-07 |
| WP4225 - pyrimidine metabolism and related diseases   | Q14117     | Dihydropyrimidinase                       | 100.00                                       | 1.99E-16 |
| WP4146 - macrophage markers                           | P61626     | Lysozyme C                                | 1.71   | 5.68E-04 |
| WP206 - fatty acid omega oxidation*                   | P00352     | Retinal dehydrogenase 1                   | 2.42   | 9.10E-07 |
| WP497 - urea cycle and metabolism of amino groups     | P50440     | Glycine amidinotransferase, mitochondrial | 100.00                                       | 1.99E-16 |
| WP2533 - glycerophospholipid biosynthetic pathway*    | P14555     | Phospholipase A2, membrane associated     | 1.90   | 3.30E-05 |
| WP3580 - methionine de novo and salvage pathway       | Q9UHY7     | Enolase-phosphatase E1                    | 1.83   | 8.52E-03 |
| WP1539 - angiogenesis                                 | P35625     | Metalloproteinase inhibitor 3             | 1.73   | 4.28E-04 |
| WP2878 - PPAR alpha pathway*                          | P07148     | Fatty acid-binding protein, liver         | 100.00                                       | 1.99E-16 |
| WP167 - eicosanoid synthesis*                         | P14555     | Phospholipase A2, membrane associated     | 1.90   | 3.30E-05 |

D KEGG database (Human) - OA/T2DM\* group


| Pathway description                             | Protein ID | Protein name                                   | OA/T2DM* vs OA/T2DM <sup>-</sup> |          |
|---|------------|--|----------------------------------|----------|
|   |            |  | Fold change                      | P-value  |
| fat digestion and absorption*                   | P07148     | Fatty acid-binding protein, liver              | 100.00                           | 1.99E-16 |
|   | P14555     | Phospholipase A2, membrane associated          | 1.90                             | 3.30E-05 |
|   | P06727     | Apolipoprotein A-IV                            | 1.59                             | 2.83E-03 |
| pantothenate and CoA biosynthesis* <sup>2</sup> | Q14117     | Dihydropyrimidinase                            | 100.00                           | 1.99E-16 |
| renin-angiotensin system                        | P08473     | Nepriylsin                                     | 100.00                           | 1.99E-16 |
| vitamin digestion and absorption*               | P06727     | Apolipoprotein A-IV                            | 1.59                             | 2.83E-03 |
| alpha-linolenic acid metabolism*                | P14555     | Phospholipase A2, membrane associated          | 1.90                             | 3.30E-05 |
| linoleic acid metabolism*                       | P14555     | Phospholipase A2, membrane associated          | 1.90                             | 3.30E-05 |
| beta-alanine metabolism                         | Q14117     | Dihydropyrimidinase                            | 100.00                           | 1.99E-16 |
| pancreatic secretion                            | P14555     | Phospholipase A2, membrane associated          | 1.90                             | 3.30E-05 |
|   | A8K714     | Calcium-activated chloride channel regulator 1 | 3.00                             | 6.17E-09 |
| drug metabolism                                 | Q03013     | Glutathione S-transferase Mu 4                 | 100.00                           | 1.99E-16 |
|   | Q14117     | Dihydropyrimidinase                            | 100.00                           | 1.99E-16 |
| glycine, serine and threonine metabolism        | P50440     | Glycine amidinotransferase, mitochondrial      | 100.00                           | 1.99E-16 |



**Table S4. Assignments of 15 lipid species based on targeted MS/MS experiments performed at high-mass resolution. (\*) 3 lipids were tentatively assigned.**

| Precursor<br><i>m/z</i> | MS/MS fragments  | Assignment                 | Appm<br>error | Characteristic of |
|-------------------------|--|----------------------------|---------------|-------------------|
| 732.55406               | 714.59 (H <sub>2</sub> O loss)<br>673.34 (N(CH <sub>3</sub> ) <sub>3</sub> neutral loss)<br>184.00 (Phosphocholine)  | [PC 32:1+H] <sup>+</sup>   | 0.1           | Superficial layer |
| 734.56996               | 716.50 (H <sub>2</sub> O loss)<br>675.34 (N(CH <sub>3</sub> ) <sub>3</sub> neutral loss)<br>184.00 (Phosphocholine)  | [PC 32:0+H] <sup>+</sup>   | 0.8           | Superficial layer |
| 756.55189               | 697.42 (N(CH <sub>3</sub> ) <sub>3</sub> neutral loss)<br>573.50 (Headgroup neutral loss)<br>184.00 (Phosphocholine)<br>146.83 (Cyclophosphane + Na)       | [PC 32:0+Na] <sup>+</sup>  | 0.8           | Superficial layer |
| 758.57007               | 740.42 (H <sub>2</sub> O loss)<br>699.42 (N(CH <sub>3</sub> ) <sub>3</sub> neutral loss)<br>575.50 (Headgroup neutral loss)<br>184.00 (Phosphocholine)     | [PC 34:2+H] <sup>+</sup>   | 0.9           | Superficial layer |
| 760.58559               | 742.59 (H <sub>2</sub> O loss)<br>701.42 (N(CH <sub>3</sub> ) <sub>3</sub> neutral loss)<br>577.42 (Headgroup neutral loss)<br>184.00 (Phosphocholine)     | [PC 34:1+H] <sup>+</sup>   | 0.7           | Superficial layer |
| 780.55218 *             | 721.50 (N(CH <sub>3</sub> ) <sub>3</sub> neutral loss)<br>597.50 (Headgroup neutral loss)<br>184.00 (Phosphocholine)                                       | [PC 34:2+Na] <sup>+</sup>  | 0.3           | Superficial layer |
| 782.56773               | 723.50 (N(CH <sub>3</sub> ) <sub>3</sub> neutral loss)<br>599.50 (Headgroup neutral loss)<br>577.33 (Headgroup Na neutral loss)<br>184.00 (Phosphocholine) | [PC 34:1+Na] <sup>+</sup>  | 0.9           | Superficial layer |
| 785.65389               | 767.59 (H <sub>2</sub> O loss)<br>726.50 (N(CH <sub>3</sub> ) <sub>3</sub> neutral loss)<br>602.50 (Headgroup neutral loss)<br>184.00 (Phosphocholine)     | [SM 40:2;2+H] <sup>+</sup> | 1.0           | Superficial layer |
| 786.60121               | 768.59 (H <sub>2</sub> O loss)<br>727.50 (N(CH <sub>3</sub> ) <sub>3</sub> neutral loss)<br>184.00 (Phosphocholine)  | [PC 36:2+H] <sup>+</sup>   | 0.6           | Superficial layer |

|             |  |                              |     |   |
|-------------|--|------------------------------|-----|---|
| 787.66935   | 769.67 (H <sub>2</sub> O loss)<br>728.42 (N(CH <sub>3</sub> ) <sub>3</sub> neutral loss)<br>604.33 (Headgroup neutral loss)<br>184.00 (Phosphocholine) | [SM 40:1;2+H] <sup>+</sup>   | 0.8 | Superficial layer                             |
| 788.61708   | 770.67 (H <sub>2</sub> O loss)<br>729.42 (N(CH <sub>3</sub> ) <sub>3</sub> neutral loss)<br>605.42 (Headgroup neutral loss)<br>184.00 (Phosphocholine) | [PC 36:1+H] <sup>+</sup>     | 0.9 | Superficial layer                             |
| 806.56757 * | 747.50 (N(CH <sub>3</sub> ) <sub>3</sub> neutral loss)<br>623.50 (Headgroup neutral loss)<br>184.00 (Phosphocholine)                                   | [PC 36:3+Na] <sup>+</sup>    | 0.4 | Superficial layer                             |
| 703.57548   | 685.50 (H <sub>2</sub> O loss)<br>644.42 (N(CH <sub>3</sub> ) <sub>3</sub> neutral loss)<br>184.00 (Phosphocholine)                                    | [SM 34:1;2+H] <sup>+</sup>   | 0.8 | OA/T2DM <sup>-</sup> patients                 |
| 725.55744   | 707.42 (H <sub>2</sub> O loss)<br>666.42 (N(CH <sub>3</sub> ) <sub>3</sub> neutral loss)<br>542.42 (Headgroup neutral loss)<br>184.00 (Phosphocholine) | [SM 34:1;2+Na] <sup>+</sup>  | 0.8 | OA/T2DM <sup>-</sup> patients                 |
| 731.60674   | 713.59 (H <sub>2</sub> O loss)<br>672.42 (N(CH <sub>3</sub> ) <sub>3</sub> neutral loss)<br>184.00 (Phosphocholine)                                    | [SM 36:1;2+H] <sup>+</sup>   | 0.7 | OA/T2DM <sup>-</sup> patients                 |
| 753.58865 * | 694.50 (N(CH <sub>3</sub> ) <sub>3</sub> neutral loss)<br>570.25 (Headgroup neutral loss)<br>184.08 (Phosphocholine)                                   | [SM 36:1;2+Na] <sup>+</sup>  | 0.7 | OA/T2DM <sup>-</sup> patients                 |
| 552.33050   | 492.31 (C <sub>2</sub> H <sub>4</sub> O <sub>2</sub> loss)<br>267.23 (FA 17:1(+O))<br>153.00 (Lysophosphocholine)                                      | [LPC 17:1+HCOO] <sup>-</sup> | 0.4 | OA/T2DM <sup>+</sup> patients &<br>Deep layer |
| 554.34672   | 494.32 (C <sub>2</sub> H <sub>4</sub> O <sub>2</sub> loss)<br>269.25 (FA 17:0(+O))<br>153.00 (Lysophosphocholine)                                      | [LPC 17:0+HCOO] <sup>-</sup> | 0.7 | OA/T2DM <sup>+</sup> patients                 |



**Figure S1. Sample collection and processing.** Human cartilage was obtained from patients undergoing total knee replacement. The tissues were cut into punches of 8 mm. Unwounded cartilage punches were isolated from the wounded tissue macroscopically. The unwounded cartilage punches were heat stabilized to avoid molecular degradation before being snap-frozen in liquid nitrogen. Finally, 12  $\mu$ m thick sections were prepared for either label-free proteomics or MALDI-MSI experiments.





Figure S2. Example of the spatial distribution of SM and LPC species in OA/T2DM<sup>-</sup> and OA/T2DM<sup>+</sup> patients.



**Figure S3. Linear discriminant analysis of superficial and deep layers of both groups independently.** Discriminant function 1 scaled loading spectrum of (A) OA/T2DM<sup>-</sup> and OA/T2DM<sup>+</sup> superficial layers and (B) OA/T2DM<sup>-</sup> and OA/T2DM<sup>+</sup> deep layers.